BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2629 related articles for article (PubMed ID: 7556068)

  • 1. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
    Wallasch C; Weiss FU; Niederfellner G; Jallal B; Issing W; Ullrich A
    EMBO J; 1995 Sep; 14(17):4267-75. PubMed ID: 7556068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
    Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
    J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells.
    Fiddes RJ; Janes PW; Sanderson GM; Sivertsen SP; Sutherland RL; Daly RJ
    Cell Growth Differ; 1995 Dec; 6(12):1567-77. PubMed ID: 9019162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axonal neuregulin signals cells of the oligodendrocyte lineage through activation of HER4 and Schwann cells through HER2 and HER3.
    Vartanian T; Goodearl A; Viehöver A; Fischbach G
    J Cell Biol; 1997 Apr; 137(1):211-20. PubMed ID: 9105049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2.
    Zhang K; Sun J; Liu N; Wen D; Chang D; Thomason A; Yoshinaga SK
    J Biol Chem; 1996 Feb; 271(7):3884-90. PubMed ID: 8632008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct characteristics of heregulin signals mediated by HER3 or HER4.
    Weiss FU; Wallasch C; Campiglio M; Issing W; Ullrich A
    J Cell Physiol; 1997 Nov; 173(2):187-95. PubMed ID: 9365520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3.
    Carraway KL; Soltoff SP; Diamonti AJ; Cantley LC
    J Biol Chem; 1995 Mar; 270(13):7111-6. PubMed ID: 7535767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heregulin-stimulated signaling in rat pheochromocytoma cells. Evidence for ErbB3 interactions with Neu/ErbB2 and p85.
    Gamett DC; Greene T; Wagreich AR; Kim HH; Koland JG; Cerione RA
    J Biol Chem; 1995 Aug; 270(32):19022-7. PubMed ID: 7642563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG; Ethier SP
    Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein.
    Kim HH; Vijapurkar U; Hellyer NJ; Bravo D; Koland JG
    Biochem J; 1998 Aug; 334 ( Pt 1)(Pt 1):189-95. PubMed ID: 9693119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase.
    Vijapurkar U; Cheng K; Koland JG
    J Biol Chem; 1998 Aug; 273(33):20996-1002. PubMed ID: 9694850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of cyclooxygenase-2 pathway by HER2 receptor.
    Vadlamudi R; Mandal M; Adam L; Steinbach G; Mendelsohn J; Kumar R
    Oncogene; 1999 Jan; 18(2):305-14. PubMed ID: 9927187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.
    Kim S; Han J; Shin I; Kil WH; Lee JE; Nam SJ
    Exp Mol Med; 2012 Aug; 44(8):473-82. PubMed ID: 22627808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins.
    Jeschke M; Wels W; Dengler W; Imber R; Stöcklin E; Groner B
    Int J Cancer; 1995 Mar; 60(5):730-9. PubMed ID: 7860149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4.
    Chen X; Levkowitz G; Tzahar E; Karunagaran D; Lavi S; Ben-Baruch N; Leitner O; Ratzkin BJ; Bacus SS; Yarden Y
    J Biol Chem; 1996 Mar; 271(13):7620-9. PubMed ID: 8631797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ErbB3 and ErbB2/neu mediate the effect of heregulin on acetylcholine receptor gene expression in muscle: differential expression at the endplate.
    Altiok N; Bessereau JL; Changeux JP
    EMBO J; 1995 Sep; 14(17):4258-66. PubMed ID: 7556067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
    Tan M; Grijalva R; Yu D
    Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
    Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
    Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
    Alimandi M; Romano A; Curia MC; Muraro R; Fedi P; Aaronson SA; Di Fiore PP; Kraus MH
    Oncogene; 1995 May; 10(9):1813-21. PubMed ID: 7538656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
    Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
    Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 132.